XML 56 R46.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

Kolltan Acquisition (Details) - Kolltan - USD ($) $ in Millions | Jul. 15, 2022 | Nov. 29, 2016
--- | --- | ---
Kolltan Acquisition |  |
Shares issued as part of consideration (in shares) |  | 1,217,200
Execution of the settlement agreement | $ 15.0 |
Milestone payments made in cash upon Successful Completion of a Phase 2 Clinical Trial | 12.5 |
Milestone payment payable upon regulatory approval of a Surviving Company Product | 52.5 |
Specified development, regulatory approvals or sales-based milestones |  |
Kolltan Acquisition |  |
Potential milestone payments |  | $ 172.5
Milestone payment payable upon regulatory approval of a Surviving Company Product | $ 172.5 |

X
- Definition Represents the business combination contingent consideration settlement agreement amount paid. + References No definition available. + Details
Name: | cldx_BusinessCombinationContingentConsiderationSettlementAgreementAmountPaid
Namespace Prefix: | cldx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the business combination contingent consideration settlement agreement amount payable. + References No definition available. + Details
Name: | cldx_BusinessCombinationContingentConsiderationSettlementAgreementAmountPayable
Namespace Prefix: | cldx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Cash outflow for milestone payments made by the company for Successful Completion of a Clinical Trial. + References No definition available. + Details
Name: | cldx_CashOutflowForMilestonePaymentsMadeUponSuccessfulCompletionOfClinicalTrial
Namespace Prefix: | cldx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of shares of equity interests issued or issuable to acquire entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1 + Details
Name: | us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5 + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=cldx_KolltanPharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=cldx_ContingentMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |